Posted by Michael Wonder on 28 Apr 2020
Shionogi receives European Commission marketing authorisation for Fetcroja (cefiderocol) for the treatment of infections due to aerobic gram-negative bacteria in adults with limited treatment options
27 April 2020 - Cefiderocol is the world’s first siderophore cephalosporin that uses the bacteria’s own iron uptake system to gain entry into the cell, acting like a Trojan horse.
Shionogi and its European subsidiary, Shionogi B.V. today announces that the European Commission (EC) has granted a marketing authorisation for cefiderocol, a new antibiotic for the treatment of infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options.
The European Commission approval of cefiderocol was based on the non-clinical data package, including the PK/PD data package.
